Evidence map›Paper›PMID 28757634›Full record

ArticleNature reviews. Nephrology2017

Experimental concerns regarding suPAR-related proteinuria.

Laurent Mesnard, Yosu Luque, Eric Rondeau

Abstract readComment
PubMed Publisher
In one paragraph

Article in Nature reviews. Nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.Kidney diseases (Basel, Switzerland) · 2021
    Review
  2. c-Src is in the effector pathway linking uPAR and podocyte injury.The Journal of clinical investigation · 2019
    Article
  3. SuPAR and FSGS: is the jury still out?Nature reviews. Nephrology · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Laurent MesnardUMR_S 1155 Institut National de la Santé et de la Recherch Médicale (Inserm), Rare and Common Kidney Diseases, Matrix Remodeling and Tissue Repair, 4 Rue de la chine, Paris, France; at Sorbonne Universités, UPMC Université, Paris, France; and at Assistance Publique - Hôpitaux de Paris, Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Paris, France.
Yosu LuqueUMR_S 1155 Institut National de la Santé et de la Recherch Médicale (Inserm), Rare and Common Kidney Diseases, Matrix Remodeling and Tissue Repair, 4 Rue de la chine, Paris, France; at Sorbonne Universités, UPMC Université, Paris, France; and at Assistance Publique - Hôpitaux de Paris, Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Paris, France.
Eric RondeauUMR_S 1155 Institut National de la Santé et de la Recherch Médicale (Inserm), Rare and Common Kidney Diseases, Matrix Remodeling and Tissue Repair, 4 Rue de la chine, Paris, France; at Sorbonne Universités, UPMC Université, Paris, France; and at Assistance Publique - Hôpitaux de Paris, Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone MarrowKidney DiseasesHumansMyeloid CellsProteinuriaReceptors, Urokinase Plasminogen ActivatorReceptors, Urokinase Plasminogen Activator

Identifiers

PMID28757634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.